# US 2026/0098077 A1 · Method for treating membranous nephropathy with taci-fc fusion protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098077 A1
- Document ID: US20260098077A1
- Status: Published application
- Kind: A1
- Application number: 19/114,798
- Filed: 2023-09-28
- Published: 2026-04-09
- Earliest claimed: 2022-09-30
- Assignees: Remegen Co., Ltd.
- Applicants: Remegen Co., Ltd.
- Inventors: Xiangdong YANG; Ling GUO; Dengren LI; Jianmin FANG; Wenxiang WANG
- Web page: https://patentgrep.com/patent/US20260098077A1

## CPC

- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61P 13/12: of the kidneys
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a drug, a dosage scheme, an administration interval, and an administration mode for treating membranous nephropathy with a TACI-Fc fusion protein. Results show that the TACI-Fc fusion protein provided by the present disclosure shows relatively good clinical curative effect and good safety in the process of treating a patient with membranous nephropathy.

## Claims

### Claim 1

A method of treating membranous nephropathy, comprising administering a therapeutically effective amount of a TACI-Fc fusion protein to a patient with membranous nephropathy, wherein the TACI-Fc fusion protein comprises:
(i) a TACI extracellular region or a fragment thereof binding to Blys and/or APRIL; and
(ii) a fragment of human immunoglobulin constant region.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the TACI extracellular region or the fragment thereof binding to Blys and/or APRIL comprises an amino acid sequence set forth in SEQ ID NO: 1.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the human immunoglobulin is IgG1, or the fragment of human immunoglobulin constant region comprises an amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 2.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the fragment of human immunoglobulin constant region comprises one or more modifications of amino acid at positions 3, 8, 14, 15, 17, 110, 111 or 173 of SEQ ID NO: 2.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the modification is substitution, deletion or insertion of an amino acid.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the substitution is selected from the group consisting of P3T, L8P, L14A, L15E, G17A, A110S, P111S and A173T.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the fragment of human immunoglobulin constant region comprises an amino acid sequence set forth in SEQ ID NO: 3.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the TACI-Fc fusion protein has an amino acid sequence set forth in SEQ ID NO: 4.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the TACI-Fc fusion protein is Telitacicept.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the membranous nephropathy includes primary membranous nephropathy or secondary membranous nephropathy.

### Claim 11 (depends on 10)

The method according to claim 10, wherein membranous nephropathy is expressed as PLA2R positive or PLA2R negative.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the patient is an adult patient or a child patient.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the patient has previously received a treatment regimen for membranous nephropathy.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the TACI-Fc fusion protein is administered at a single dose of about 0.1 to 10 mg/kg.

### Claim 15 (depends on 12)

The method according to claim 12, wherein the TACI-Fc fusion protein is administered at a single dose of 160 to 240 mg, further preferably 160 mg or 240 mg.

### Claim 16 (depends on 12)

The method according to claim 12, wherein the TACI-Fc fusion protein is administered subcutaneously, intramuscularly or intravenously, or at a thigh, abdomen or upper arm.

### Claim 17 (depends on 12)

The method according to claim 12, wherein the TACI-Fc fusion protein is administered 2-4 times at an interval of one month and/or the administration lasts for about 2 to 50 weeks.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the TACI-Fc fusion protein is administered at a frequency of once a week.
